CDK (cyclin-dependent kinase) inhibitor

Abemaciclib - Palbociclib - Ribociclib      

Select            
Trial Studied trt Control trt patientstagsROB Trial resultprogression or death (progression free survival PFS)

advanced breast cancer (metastatic)

abemaciclib
MONARCH 3, 2017        NCTAbemaciclib +nsAInsAI 1st line HER-2 negative HR positive postmenopausal Low risk of bias conclusive-46%
palbociclib
PALOMA 3, 2015            NCTpalbociclib + fulvestrantfulvestrant alone2nd line 2nd line HER-2 negative HR positive Low risk of bias conclusive-58%
PALOMA-2, 2016      NCTpalbociclib + letrozoleletrozole alonefirst line 1st line HER-2 negative HR positive postmenopausal Low risk of bias conclusive-42%
PALOMA 1/TRIO-18, 2015      NCTpalbociclib + letrozoleletrozole alone 1st line HER-2 negative HR positive postmenopausal Exploratory suggesting-51%
ribociclib
MONALEESA-2, 2016        NCTribociclib (LEE011) + letrozoleletrozole alonefirst line 1st line HER-2 negative HR positive postmenopausal Low risk of bias conclusive-44%

lung cancer (metastatic)

abemaciclib
JUNIPER, 2018      NCTabemacicliberlotinib2nd lineRisk of bias remark